SCHEMBL13805348

SCHEMBL13805348

c1ccc(-c2nnc(-c3ccccc3)n2-c2ccc(N(c3ccc(-n4c5ccccc5c5ccccc54)cc3)c3ccc4c(c3)C3(c5ccccc5-c5ccccc53)c3ccccc3-4)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
GLA P06280 1/20 0.33
HSD11B1 P28845 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
AVPR1A P37288 1/20 0.33
AKT1 P31749 2/20 0.32
OXTR P30559 1/20 0.31
ESR1 P03372 1/20 0.30
ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13805258 0.98 HPGD (0.37) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805332 0.97 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805366 0.97 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805240 0.95 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805170 0.95 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805350 0.95 KDM4E (0.33) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805302 0.94 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805160 0.94 HPGD (0.36) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805259 0.93 HPGD (0.35) KDM4EATML3MBTL1HPGDSMN1; SMN2
SCHEMBL13805043 0.92 KDM4E (0.37) KDM4EATML3MBTL1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906518-B2 Triazole derivative, light-emitting element, light-emitting device, and electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-12-09 US disclosed
US-8906518-B2 Triazole derivative, light-emitting element, light-emitting device, and electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-12-09 US disclosed
US-20090160324-A1 Triazole Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-25 US disclosed
US-20090160324-A1 Triazole Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090160324-A1 Triazole Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Device GRIN3A, TEAD2, TBL3 KDM4E 2154/4885ATM 2094/4885L3MBTL1 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.